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Purpose: Though postoperative radiation for esophageal squamous cell carcinoma is offered in selected cases,
there is conflicting evidence as to whether it improves overall survival (OS). A retrospective investigation was
performed to analyze the prognostic impact of postoperative radiation therapy (PORT) in a large cohort of patients.
Methods: From 2001 to 2009, 725 patients underwent radical esophagectomy (R0) with or without PORT were
eligible for retrospective analysis. Patients were grouped into surgery alone (n = 467) and surgery plus PORT
(n = 258). Median irradiation doses were 50 Gy (range: 40-56 Gy). Radiation fields encompassed the bilateral
supraclavicular fossa, mediastinum, subcarinal area, and the tumor bed for the upper/middle-third disease; the
bilateral supraclavicular fossa, mediastinum, the tumor bed, subcarinal area, and lower thoracic paraesophageal area
for the lower-third disease. Kaplan-Meier and Cox regression analysis were used to compare OS.
Results: After median follow-up of 53 months, the median OS was 29 months in the PORT group and 23 months
in the surgery alone group. The addition of PORT improved OS at 3 years from 36.6 to 43.6% compared with
surgery alone. The use of PORT was associated with significantly improved OS (p = 0.018). For American Joint
Committee on Cancer (AJCC) stage III esophageal cancer (T1-2N2M0, T3N1-2M0, T4N1-3M0), there was significant
improvement in OS (p = 0.002) in the PORT group, not only for lymph-node metastatic ratio (LNMR) ≥0.25
(p = 0.001), but also for LNMR <0.25 (p = 0.043). However, for stage IIB disease (T1-2N1M0) there was no significant
differences. The addition of POCT didn’t prolong the OS significantly (Surgery alone group, p = 0.079; PORT group,
p = 0.111).
Conclusions: This large retrospective analysis supports the use of PORT for pathologic lymph node positive stage III
esophageal squamous cell carcinoma. Given the retrospective nature of this study, the results should be confirmed
by appropriately powered randomized trials. Further development of adjuvant therapy in EC is warranted.
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Esophageal cancer (EC) is the eighth most common can-
cer worldwide, and especially in some areas of China is
the fourth most common cause of death and is of squa-
mous cell carcinoma (SCC) histology in >90% of cases
[1]. For many decades, surgical resection was the only
choice for these patients. However, surgery alone has
been associated with low cure rates, regardless of surgi-
cal approach or histology. Loco-regional recurrence and
metastatic spread remain common, despite improvement
in surgical techniques and perioperative care. High rates
of local and systemic failure have prompted investigation
into the multidisciplinary management of those with lo-
cally advanced esophageal cancer using neoadjuvant and
adjuvant approaches with radiotherapy, chemotherapy,
and chemoradiotherapy in an attempt to reduce loco-
regional recurrence, and to improve outcome after the
surgery. Preoperative radiotherapy and chemotherapy
are being used more often, and neoadjuvant chemora-
diotherapy is currently the standard of care in many
western countries [2-8]. Whether or not postoperative
radiotherapy (PORT) and/or postoperative chemother-
apy (POCT) affects treatment outcomes, however, re-
mains controversial [9-12].
In this study, a retrospective investigation was
performed to 1) identify the postoperative risk factors
influencing the outcome following esophagectomy in re-
sectable esophageal squamous cell carcinoma (ESCC)
with pathologic lymph nodes positive; 2) propose indica-
tions for or against PORT for patients with pathologic-
ally positive lymph nodes ESCC after surgery.
Patients and methods
Patients’ data
From 2001 to 2009, 1331 patients with thoracic ESCC
underwent radical esophagectomy (R0) with or without
PORT and/or POCT at a single institution. Patients eli-
gible for the analysis were those with stage T1-4N1-3M0
ESCC. Patients with stage T3-4N0M0 disease were ex-
cluded. This was done to remove possible bias, because
most patients with T3-4N0M0 disease received PORT
which just encompassed the tumor bed. Thus, the com-
parison was strictly limited to those with stage T1-4N1-
3M0 ESCC who received PORT with the regional lymph
node and the tumor bed.
Only patients who survived for more than 3 months
postsurgery were included in the cohort. This was done
to remove possible bias in favor of the PORT group,
because some of the patients who received surgery alone
might have died in the perioperative period before re-
ceiving adjuvant radiation. Thus, the comparison was
limited to those who were treated with definitive
esophagectomy with or without adjuvant radiation
therapy.Other essential conditions: no distant metastasis, no
preoperative chemotherapy and/or radiotherapy, no in-
vasion to cervical esophagus and cardiac part of the
stomach.
The present study was approved by the Ethical Review
Committee at the hospital (No. zjzlyy-2013-04-87). Rec-
ommendations of the Declaration of Helsinki for bio-
medical research involving human subjects were also
followed.
Staging
Tumor size and extent is coded primarily from the
operative report and pathology reports and therefore
represents pathologic staging. Extent of nodal disease
was determined based on pathologic findings only. This
information was used to convert the extent of disease
to tumor, node, metastasis staging according to the
American Joint Committee on Cancer (AJCC) staging,
7th edition [13]. Table 1 lists the included patients based
on their tumor, node, metastasis classification and AJCC
stage grouping.
Surgery
All patients underwent radical surgery. The standard
surgical approach consisted of a limited thoracotomy on
the right side and intrathoracic gastric tube reconstruc-
tion (Ivor-Lewis procedure) for lesions in the middle/
lower-third of the esophagus. Upper-third lesions were
treated by neck anastomosis (Mackeown procedure).
Most patients underwent two-field lymph node dissec-
tion. No pyloroplasty or feeding jejunostomy was per-
formed. A nasogastric tube was placed in each patient
until anastomotic sites were closed as assessed by
esophagography on post operation day 14.
Postoperative adjuvant radiotherapy and chemotherapy
In this study, all patients were considered for the PORT
and POCT. As the role of PORT and POCT for ESCC
was controversial at the time of the treatment of these
patients, the utilization of these postoperative adjuvant
therapy was thus according to the individual physicians’
preference and the general physical conditions of the pa-
tient. Patients with poor prognostic factors such as poor
performance status, delayed recovery from surgery, mul-
tiple comorbidities, etc did not undergo these adjuvant
therapy.
PORT was given to patients with postoperative T1-
4N1-3M0 initiated 3 to 4 weeks after the surgery. The
extent of the irradiation field was determined based on
the primary site in the esophagus. Large T-shaped fields
were used that encompassed the tumor bed, bilateral
supraclavicular fossa, mediastinum, and subcarinal area
for lesions in the upper/middle-third lesions of the
esophagus; the tumor bed, bilateral supraclavicular fossa,
Table 1 Patient characteristics based on TNM classification and AJCC stage grouping
Stage Grouping PORT Surgery alone Total No. of Patients
T1-2N1 IIB 20 52 72
T1-2N2 IIIA 23 19 42
T3N1 IIIA 85 167 252
T3N2 IIIB 69 119 188
T4N1-3 IIIC 61 110 171
Total No. of Patients 258 467 725
TNM, tumor, node, metastases based classification; AJCC, American Joint Committee on Cancer; PORT, postoperative radiation therapy.
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paraesophageal lymph nodes area for lesions in the
lower-third lesions of the esophagus. Radiation was
given through anteroposterior fields first to 36-40 Gy at
1.8-2 Gy per fraction followed by parallel opposing ob-
lique fields to 10-20 Gy to avoid the spinal cord. Ten
MV photons were used to deliver the radiation to the
mediastinum through anteroposterior and oblique fields.
The bilateral supraclavicular fossas were followed by
9-12 MeV electrons 10-20 Gy. Median irradiation dose
was 50 Gy (range: 40-56 Gy). In some cases, targets were
shrunk on the basis of the patient’s condition or the phy-
sician’s judgment. After 2005, the planning target vol-
ume has been irradiated by multiple field arrangement
with the use of IMRT techniques. Dose volume histo-
grams for the planning target volume, spinal cord, lung
and heart have been calculated in order to gain full
knowledge of the 3D dose distribution. The maximum
dose to the spinal cord was limited to 45 Gy at any
point. The volume of both lungs that received more than
20 Gy (V20) was ≤25% and the heart received 40 Gy
(V40) < 50%.
Cisplatin and 5-fluorouracil (≥2 cycles) were used
most frequently (70%), although several other chemo-
therapeutics were also used. Most of patients received
sequential chemoradiotherapy. Some patients with good
performance status received concurrent chemora-
diotherapy.Statistical analysis
Overall survival (OS) was determined as the time
(in months) from the date of surgery to last follow-up or
to the date of death. Survival probabilities were calcu-
lated by Kaplan-Meier method and compared by the
log-rank test. Multivariate analysis was performed by
Cox regression model. Variables in the analysis included
gender, age, tumor length, pathologic T-category, patho-
logic N-category, LNMR, tumor differentiation, PORT,
and POCT. Statistical analysis was performed using
SPSS software, Version 13.0 (SPSS Inc., Chicago, IL). All
probability values were two-sided and p values < 0.05
were considered statistically significant.Results
A total of 725 patients who underwent radical
esophagectomy (R0) were included in the present study:
258 (35.6%) received PORT, 262 (36.1%) received POCT.
In 258 PORT patients, 167 (64.7%) received adjuvant
chemotherapy, 21 (8.1%) was applied simultaneously.
PORT was generally well tolerated. Main toxicity (grade 3
or greater, %): neutropenia 12 (4.7%), thrombocytopenia 5
(1.9%), anaemia 12 (4.7%), nausea/vomiting 11 (4.2%), an-
orexia 15 (5.8%), dysphagia 30 (11.6%), radiation pneu-
monitis 17 (6.6%) and fatigue 30 (11.6%). Most side effects
were grade I/II and well tolerated by supportive care. The
median age of all patients was 56 (range 32–86). Median
follow-up period for the surviving patients was 53 months
(range 1–97 months). Table 2 lists available patient char-
acteristics and the comparisons by treatment assignment.
Patients who received PORT were more often male, < 65
years old and tumor length ≥ 5cm disease.
Overall survival
The data regarding survival was available for all patients.
After median follow-up of 53 months, the median OS
was 29 months in the PORT group and 23 months in
the surgery alone group. The addition of PORT im-
proved OS at 3 years from 36.6 to 43.8% compared with
surgery alone. The use of PORT was associated with sig-
nificantly improved OS (p = 0.018). For American Joint
Committee on Cancer (AJCC) stage III esophageal can-
cer (T1-2N2M0, T3N1-2M0, T4N1-3M0), 414 patients
received surgery alone and 238 patients received PORT.
Median OS improved from 21 months to 29 months,
and 3-year OS improved from 33.7 to 44.9% (p = 0.002)
(Figure 1). However, for stage IIB disease (T1-2N1M0)
there was no significant differences.
Univariate and multivariate analyses
On unvariate analysis, PORT (hazard ratio [HR] 0.79,
95% confidence interval [CI] 0.65 – 0.97, p = 0.018) was
associated with improved survival. POCT did not signifi-
cantly improve OS. Male, ≥65 years old, higher T cat-
egory, more lymph nodes metastases and higher LNMR
were all associated with decreased OS. On multivariate
analysis, use of PORT was again associated with
Table 2 Comparison of patient characteristics by
treatment assignment (N=725)
Variable All Patients (%) PORT Pa
Yes No
Gender 0.029
Female 68(9) 16(6) 52(11)
Male 657(91) 242(94) 415(89)
Age 0.004
< 65 564(78) 216(84) 348(75)
≥65 161(22) 42(16) 119(25)
Tumor length 0.012
< 5cm 391(54) 123(48) 268(57)
≥5cm 334(46) 135(52) 199(43)
pT-category 0.137
T1-2 123(17) 42(16) 81(17)
T3 546(75) 198(77) 348(75)
T4 56(8) 18(7) 38(8)
pN-category 0.682
N1 351(49) 121(47) 230(49)
N2 227(31) 86(33) 141(30)
N3 147(20) 51(20) 96(21)
LNMR 0.983
< 0.25 582(81) 207(80) 375(80)
≥0.25 143(19) 51(20) 92(20)
Tumor differentiation 0.469
High (G1) 90(12) 35(13) 55(12)
Moderate (G2) 479(66) 176(68) 303(65)
Low (G3) 156(22) 49(19) 107(23)
POCT <0.001
Yes 262(36) 167(65) 95(20)
No 463(64) 91(35) 372(80)
a X2 p value; LNMR, lymph-node metastatic ratio; PORT, postoperative radiation
therapy; POCT, postoperative chemotherapy.
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p = 0.001). Male gender, higher T stage and more lymph
nodes metastases were again associated with decreased
survival (Table 3).
Overall survival by metastatic lymph-node ratio
A total of 375 patients with LNMR < 0.25 received sur-
gery alone, compared with 207 patients who received
PORT. Median OS was improved from 30 months to 34
months with the addition of PORT as well as an im-
provement in 3-year OS from 43.7 to 46.2%, but there
was no significant difference (p = 0.191). When these pa-
tients were grouped by AJCC stage, there was no OS
benefit for IIB disease (p = 0.062). For stage III LNMR <
0.25, 323 patients received surgery alone and 188patients received PORT. Median OS improved from 29
months to 35 months, and 3-year OS improved from
41.1 to 47.9% (p = 0.043) (Figure 2). Similarly, when ana-
lyzing patients with LNMR ≥0.25, there was no signifi-
cant difference for stage IIB disease (p = 0.317).
However, for stage III disease, median OS improved
from 11 months to 18 months, and 3-year OS improved
from 9.2 to 24.5% (p = 0.001) (Figure 3).
Overall survival by combining chemotherapy
A total of 167 patients received PORT combined with
POCT, compared with 91 patients who received PORT
alone. The median OS and 3-year OS rate were 37
months and 47.6% with PORT alone, 24 months and
40.4% with PORT plus POCT. When these patients were
treated with concurrent radiochemotherapy, median OS
was 26 months. The addition of chemotherapy didn’t
prolong the OS (p = 0.111) in PORT group. Similarly,
when analyzing patients with surgery alone group, the
median OS and 3-year OS rate were 25 months and
38.0% with surgery alone, 14 months and 30.6% with
surgery plus POCT (p = 0.079).
Discussion
The results of this large retrospective study revealed that
the addition of PORT is associated with significantly im-
proved OS for AJCC lymph node positive stage III ESCC.
When stratifying by the LNMR, the survival benefit asso-
ciated with postoperative remains for stage III disease. For
stage IIB (T1-2N1M0) patients, there was no significant
OS benefit with the use of PORT. However, in our study
the number of stage IIB patients was only 72; the limited
number of events made it difficult to evaluate OS differ-
ences for this stage disease. Other positive prognostic
factors for overall survival include gender, pathologic
T classification and N classification.
In spite of radical resection and extended lymph node
dissection, most esophageal cancer patients still die of
recurrence. Although there is no general recommenda-
tion for adjuvant radiotherapy, it has been shown that
prophylactic radiotherapy after radical operation of
esophageal cancer can reduce the local recurrence rate
[14]. In an attempt to further clarify the impact of PORT
in a prospective fashion, several randomized studies
were performed comparing PORT with surgery alone
[11,12,15-17]. However, the majority of the evidence has
revealed that PORT does not confer any survival benefit
over surgery alone. Teniere et al. evaluated 221 patients
with epidermoid carcinoma of the middle to lower third
of the esophagus who were randomized to PORT to a
dose of 45–55 Gy versus observation. They found that
although local control improved from 15 to 30%, there
was no survival benefit with the addition of PORT [15].




















Figure 1 Kaplan-Meier estimates for overall survival of patients receiving PORT compared with surgery alone for lymph nodes positive
stage III esophageal cancer. The median survival was 29 months for PORT versus 21 months for surgery alone (p = 0.002). PORT, postoperative
radiation therapy.
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that PORT significantly increased the fibrotic stricture
rate and did not improve OS or disease free survival
[12]. Therefore, there are little data to suggest that
PORT affords any survival benefit [9]. However, all of
the previous mentioned trials did not stratify the pa-
tients based on their stage and likely were not large
enough to detect an improvement in survival only for
those patients with lymph nodes positive or deeply in-
vading tumor. In addition, both Teniere et al. [15] and
Zieren et al. [12] included patients with positive celiac
nodes (stage M1). These patients are excluded from our
study and represent a cohort at much higher risk for dis-
tant failure and therefore are less likely to benefit from
PORT therapy. Adjuvant radiotherapy can theoretically
treat microscopic disease left behind after surgery and
increase local control.
Recently, Schreiber et al. performed a retrospective
review using the Surveillance Epidemiology and End Re-
sults (SEER) database to analyze whether there was sur-
vival benefit to adjuvant radiation in stage T3-4N0M0 or
T1-4N1M0 esophageal cancer who were definitively
treated with esophagectomy. A total of 1046 patients
met the selection criteria: 683 (65.3%) received surgery
alone and 363 (34.7%) received PORT. For AJCC stage
III esophageal carcinoma (T3N1M0 or T4N0-1M0), 346
patients underwent surgery alone and 231 patients re-
ceived PORT. Use of PORT resulted in an improvement
in median OS from 15 months to 19 months and an im-
provement in 3-year OS from 18.2 to 28.9% (p < 0.001),
respectively. This benefit was present for both squamouscell carcinoma and adenocarcinoma [10]. Other studies
have also addressed the impact of PORT on esophageal
squamous cell carcinoma with lymph nodes positive,
which found a survival benefit only for those with stage III
patients [11,18]. Similar to the findings mentioned above,
our study revealed that PORT significantly improved OS
for patients with lymph node positive stage III disease, and
suggested that it is essential to use proper patient selection
criteria when the decision-making for postoperative adju-
vant radiotherapy in ESCC.
The role of adjuvant chemotherapy of ESCC has been
addressed in a number of clinical phase III trials [19-21].
Ando et al. conducted a randomized multicenter trial to
determine whether POCT improves the outcome of pa-
tients with ESCC who underwent radical surgery. Their
results showed that the 5-year overall survival rate was
52% with surgery alone, and 61% with surgery plus
chemotherapy (one-sided log-rank, p = 0.13). Risk reduc-
tion by POCT was remarkable in the subgroup with
lymph node metastasis [19]. Zhang et al. conducted a
meta-analysis comprising a total of 1000 patients with
esophageal cancer (ESCC and adenocarcinoma) in 2008.
The patients with pathologically positive lymph nodes
demonstrated a positive trend towards improved sur-
vival, but this was not significant (OR, 0.76; 95% CI:
0.538‑1.083) [22]. The theoretical advantages of adding
adjuvant chemotherapy to the treatment of esophageal
cancer are for potential targeting micrometastatic dis-
ease, thus decreasing the risk of distant spread. Never-
theless, our study showed that the therapeutic efficacy of
POCT was unsatisfactory. This might be attributed to
Table 3 Univariate and mutivariate analysis for survival
Variable Univariate analysis Mutivariate analysis
CHR 95% CI P CHR 95% CI P
Gender
Female 1 1
Male 0.70 1.18-2.44 0.004 1.44 1.00-2.08 0.049
Age
< 65 1 1
≥65 1.26 1.02-1.56 0.031 1.17 0.93-1.46 0.175
Tumor length
< 5cm 1 1
≥5cm 1.01 0.84-1.22 0.897 0.95 0.79-1.15 0.618
pT-category
T1-2 1 1
T3 1.42 1.09-1.87 0.011 1.48 1.12-1.95 0.005
T4 2.65 1.82-3.87 < 0.001 2.27 1.53-3.35 <0.001
pN-category
N1 1 1
N2 1.39 1.12-1.74 0.003 1.33 1.06-1.67 0.015
N3 2.70 2.14-3.40 < 0.001 1.79 1.29-2.48 < 0.001
LNMR
< 0.25 1 1
≥0.25 2.36 1.91-2.91 < 0.001 1.54 1.14-2.07 0.004
Tumor differentiation
High (G1) 1 1
Moderate (G2) 0.88 0.66-1.17 0.383 0.88 0.67-1.19 0.423
Low (G3) 1.13 0.82-1.56 0.463 0.94 0.67-1.30 0.689
PORT
No 1 1
Yes 0.79 0.65-0.97 0.018 0.77 0.63-0.94 0.001
POCT
No 1 1
Yes 1.10 0.91-1.33 0.325 1.15 0.91-1.44 0.061
CHR, Cox hazard ratio; 95% CI, 95% Confidence Interval; LNMR, lymph-node
metastatic ratio; PORT, postoperative radiation therapy; POCT,
postoperative chemotherapy.
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therapy regimens were not quite the same among these
patients. Therefore, the therapeutic efficacy of POCT in
these patients is still no clear indication based on our
data. Recently, in a phase II non-randomized trial which
evaluated postoperative concurrent chemoradiation with
cisplatin and 5-fluorouracil in patients with poor prog-
nosis oesophageal and gastroesophageal junction (EGJ)
cancers, the 4-year overall survival, freedom from recur-
rence, distant metastatic control and locoregional con-
trol were 51%, 50%, 56% and 86% respectively for
patients with lymph node positive (T3 or T4) tumours,which are better than the historical outcomes with sur-
gery alone [23]. However, the efficacy of postoperative
chemoradiation has not been compared to surgery alone
in a randomized trial in patients with EC. Therefore,
evaluation of postoperative chemoradiotherapy for these
patients may be important. Further development of post-
operative adjuvant therapy in EC is warranted.
In addition, the use of neoadjuvant chemoradiotherapy
has become an increasingly used treatment approach.
The potential value of preoperative therapy is that adju-
vant therapy could be started immediately targeting any
micro metastatic deposits without allowing time for fur-
ther growth, and treatment would not be given until
diagnosis and staging is firmly assessed. In addition,
prior to surgery it is thought that the patient’s may be
better able to tolerate aggressive chemotherapy and radi-
ation as it can start immediately and their physical and
nutritional state has not been burden by the need to re-
cover from surgery. Results from a recent multicenter
phase III randomized trial (CROSS study) showed that
neoadjuvant chemoradiotherapy improved OS compared
to surgery alone in patients with resectable (T2-3N0-
1M0) esophageal or EGJ cancers. Median survival was
49 months in the neoadjuvant chemoradiotherapy arm
compared to 26 months in the surgery alone arm [23].
In 2011, Kranzfelder et al. published a meta-analysis
which sought to clarify the benefits of neoadjuvant treat-
ment for ESCC. Nine RCTs involving neoadjuvant
chemoradiotherapy versus surgery, eight involving
neoadjuvant chemotherapy versus surgery, and three in-
volving neoadjuvant treatment followed by surgery or
surgery alone versus definitive chemoradiotherapy were
identified. The HR for overall survival was 0.81 (95% CI:
0.70-0.95; p = 0.008) after neoadjuvant chemoradio-
therapy and 0.93 (0.81-1.08; p = 0.368) after neoadjuvant
chemotherapy. The likelihood of R0 resection was sig-
nificantly higher after neoadjuvant treatment (Chemora-
ditherapy: HR 1.15, p = 0.043; chemotherapy: HR 1.16,
p = 0.006). Morbidity rates were not increased after
neoadjuvant Chemoradiotherapy (HR 0.94, p = 0.363)
but 30-day mortality was non-significantly higher with
combined treatment. Morbidity (HR 1.03, p = 0.638) and
mortality (HR 1.04, p = 0.810) rates after neoadjuvant
chemotherapy and surgery did not differ from those
after surgery alone. The authors concluded that the pa-
tients with resectable ESCC, a significant survival benefit
for neoadjuvant chemoradiotherapy was evident, with no
increase in morbidity rate [24]. There are not well done
randomized trials to compare the outcome of postopera-
tive therapy against preoperative therapy in esophageal
cancer with modern staging and modern treatment tech-
niques. Further development of the multidisciplinary
management for patients with locally advanced esopha-




















Figure 2 Kaplan-Meier estimates for overall survival of patients receiving PORT compared with surgery alone for lymph nodes positive
stage III esophageal cancer with LNMR < 0.25. The median survival was 35 months for PORT versus 29 months for surgery alone (p = 0.043).
PORT, postoperative radiation therapy; LNMR, lymph-node metastasis ratio.
Xu et al. Radiation Oncology 2013, 8:116 Page 7 of 8
http://www.ro-journal.com/content/8/1/116compared to neoadjuvant chemoradiotherapy is warranted.
The approach is currently being explored in China by in-
vestigators of the ZTOG1201 trial, a multicenter phase II
trial of neoadjuvant and adjuvant chemoradiotherapy in
locally advanced EC (NCT01463501)[25].
In conclusion, for those who do undergo primary sur-
gery, the results of this large population-based analysis
revealed that there is an association of improved OS

















Figure 3 Kaplan-Meier estimates for overall survival of patients receiv
stage III esophageal cancer with LNMR >0.25. The median survival was
PORT, postoperative radiation therapy; LNMR, lymph-node metastasis ratio.results suggest that a subset of such patients may benefit
from aggressive local therapy. Given the retrospective
nature of this study, until appropriately powered ran-
domized trials confirm these results, caution should be
used before broadly applying these findings in clinical
practice. As a retrospective study, our results do not
have the same strength as a prospective study, however,





ing PORT compared with surgery alone for lymph nodes positive
18 months for PORT versus 11 months for surgery alone (p = 0.001).
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